该项收购完成后,Cambrex公司将获得Avista公司包括从原料药、药品开发、环化核苷酸制造,到独立分析、微生物测验以及固态科学等多项服务,同时将Avista的4个制药站点纳入其生...查看全文
琬麟2015-02-07 09:21
$凯姆布雷克斯(CBM)$ EAST RUTHERFORD, N.J., Feb. 6, 2015 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, "Cambrex") is pleased to announce that it has initiated the second significant expansion of its Charles City, Iowa facility in less than three years. Strong continu...查看全文
$凯姆布雷克斯(CBM)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2017-01-12 AccNo: 0000869311-17-000305 Size: 13 KB 网页链接
$凯姆布雷克斯(CBM)$ 8-K - Current report Filed: 2017-01-04 AccNo: 0001437749-17-000068 Size: 23 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers 网页链接
$凯姆布雷克斯(CBM)$ 内部交易: 2016-12-14,EVP & COO,Cavanagh Shawn ,卖出,30000普通股, $53.58
$凯姆布雷克斯(CBM)$ 内部交易: 2016-12-14,EVP & COO,Cavanagh Shawn ,期权,30000普通股, $15.73
$凯姆布雷克斯(CBM)$ 内部交易: 2016-11-11,执行副总裁 & CFO,SARGEN GREGORY ,卖出,22500普通股, $52.02
$凯姆布雷克斯(CBM)$ 内部交易: 2016-11-11,执行副总裁 & CFO,SARGEN GREGORY ,期权,22500普通股, $15.73
$凯姆布雷克斯(CBM)$ 内部交易: 2016-11-09,总裁 & CEO,KLOSK STEVEN M ,卖出,50000普通股, $50.87
$凯姆布雷克斯(CBM)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2016-11-09 AccNo: 0000215457-16-006948 Size: 13 KB 网页链接
$凯姆布雷克斯(CBM)$ 8-K - Current report Filed: 2016-11-04 AccNo: 0001437749-16-041072 Size: 541 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$凯姆布雷克斯(CBM)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2016-11-04 AccNo: 0001437749-16-041070 Size: 4 MB 网页链接